SynthesisJournal of neuro-oncology2019
Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Synthesis in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review.International journal of molecular sciences · 2023Pooled it
- Efficacy and safety of bevacizumab for vestibular schwannomas in neurofibromatosis type-2: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- [BMJ open · 2026Article
- Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions-A Scoping Review.Current issues in molecular biology · 2026Review
- Single-cell multi-omic techniques highlight the diverse composition and intercellular interactions of the vestibular schwannoma tumor microenvironment.Neuro-oncology advances · 2026Article
- The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.Acta neuropathologica communications · 2025Article
- Efficacy of first line of bevacizumab in patients with neurofibromatosis 2-related vestibular schwannomas.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study.Oncology letters · 2025Article
- Predicting the efficacy of bevacizumab on peritumoral edema based on imaging features and machine learning.Scientific reports · 2025Article
- Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double-Blind, Placebo-Controlled Study Proposal.Laryngoscope investigative otolaryngology · 2025Review
- Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma.Nature communications · 2025Article
- Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.Cancers · 2025Review
- Bilateral vestibular schwannoma with a cooccurring meningioma in a child: a case report and review of literature.Annals of medicine and surgery (2012) · 2024Article
- Spontaneous Regression of a Large Vestibular Schwannoma: Is Nonoperative Management Reasonable?Brain tumor research and treatment · 2024Article
- Neurocutaneous Diseases: Diagnosis, Management, and Treatment.Journal of clinical medicine · 2024Review
- Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.Brain communications · 2024Article
- Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients.Journal of neuro-oncology · 2023Article
- Culture of attenuatedHuman vaccines & immunotherapeutics · 2023Article
- The genetic landscape and possible therapeutics of neurofibromatosis type 2.Cancer cell international · 2023Review
- Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions.Pediatric neurosurgery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividual evidence suggests that the anti-angiogenic agent bevacizumab may control vestibular schwannoma (VS) growth and promote hearing preservation in patients with neurofibromatosis type 2 (NF2). However, such metadata has yet to be consolidated, as well as its side-effect profile yet to be fully understood. Our aim was to pool systematically-identified metadata in the literature and substantiate the clinical efficacy and safety of bevacizumab with respect to radiographic tumor response, hearing, and treatment outcomes.
methodsSearches of seven electronic databases from inception to March 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of outcomes was then extracted and pooled by random-effects meta-analysis of proportions.
resultsEight articles reporting 161 NF2 patients with 196 assessable VS met satisfied all criteria. Radiographic response to bevacizumab was partial regression in 41% (95% CI 31-51%), no change in 47% (95% CI 39-55%), and tumor progression in 7% (95% CI 1-15%). In patients with assessable audiometric data, bevacizumab treatment resulted in hearing improvement in 20% (95% CI 9-33%), stability in 69% (95% CI 51-85%) and additional loss in 6% (95% CI 1-15%) Serious bevacizumab toxicity was observed in 17% (95% CI 10-26%). Subsequent surgical intervention was required in 11% (95% CI 2-20%).
conclusionsBevacizumab may arrest both tumor progression and hearing loss in select NF2 patients presenting with VS lesions. However, a considerable proportion of patients are anticipated to experience serious adverse events; correspondingly, judicious use of bevacizumab for symptomatic management of VS in NF2 is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.